Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Nature·
- DOI
- 10.1038/s41586-021-03398-2
- PMID
- 33684923
- PMCID
- —
- OpenAlex
- W3123551159
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
The abstract frames these variants as relevant to COVID-19 interventions because some authorized and developing therapies and vaccines targeted earlier SARS-CoV-2 forms. The reported neutralization differences are relevant to treatment and vaccination considerations at a population-health level.
Structured evidence summary
Research question
The article examines how SARS-CoV-2 variants B.1.1.7 and B.1.351 respond to neutralization by monoclonal antibodies, convalescent plasma, and vaccine-derived sera.
Study design
The abstract describes a laboratory neutralization study comparing antibody activity against SARS-CoV-2 variants and wild-type virus. The bibliographic metadata identifies it as a peer-reviewed journal article in Nature.
Population and setting
The biological samples referenced include plasma from people who had recovered from COVID-19 and sera from vaccinated individuals. The variants are contextualized by reported detection in the United Kingdom for B.1.1.7 and South Africa for B.1.351.
Main findings
B.1.1.7 showed reduced susceptibility to many N-terminal-domain monoclonal antibodies and some receptor-binding-domain monoclonal antibodies, but the abstract reports no greater resistance to convalescent plasma or vaccine sera. B.1.351 showed broader resistance to several monoclonal antibodies and substantially reduced neutralization by convalescent plasma and vaccine sera compared with wild-type SARS-CoV-2.
Public-health relevance
The abstract frames these variants as relevant to COVID-19 interventions because some authorized and developing therapies and vaccines targeted earlier SARS-CoV-2 forms. The reported neutralization differences are relevant to treatment and vaccination considerations at a population-health level.
Important limitations
The abstract reports laboratory neutralization findings and does not provide clinical effectiveness outcomes or detailed participant/sample characteristics. This summary is limited to the supplied single-article abstract and metadata; the original paper is needed for decision-grade interpretation.
GIDS interpretation
For GIDS-style indexing, this paper is discoverable under COVID-19/SARS-CoV-2, the United Kingdom and South Africa variant contexts, and topics involving treatment, vaccination, and transmission dynamics. This is contextual classification only and does not indicate a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.